Medipharm Labs Corp T.LABS

Once LABS is associated with the name of their global pharma

[subaru1i]

partner, this stock will gain much, much, much, larger investor exposure be it retail or institutional buying for high growth mutual funds, portfolios, etc.  

The nice thing about institutionals, the buy orders are typically much larger that drives volumes and price.   

New 52 week high...imho achievable this year.  

Don't be surprised if this afternoon or tomorrow the buying volumes start to go up.

[subaru1]

Subaru1i, the way i see that to reach a new 52 week high, first i don't think that we will see that this year unless we got a really really good 3 qrt and then by the end of october we could have a new high. Otherwise we need a very good 4 qrt, Labs might receive the Monograph sometime before mid 2024 and the scheduling 1 to 3 might happen sometimes in the second half of 2024, Labs for me is a

[subaru1i]

Pidduck did mention disclosure in Q4 of their South American pharma customer once they receive their ANIVSA new drug approval, an established top tier generic drug maker in Brazil.   One of them in Brazil is 40% owned by Pfizer as well but is it the one LABS is dealing with?  We are a publicly traded company so anything could happen imho, even a hostile take over bid by any of the

[subaru1]

as you say you Labs could receive a hostile take over bid by the way i am really surprise that we haven't received one yet, this is something that keep telling me, if the potential is so high why nobody come to knock at the door, with the cash that Labs has and all the certification they have why are we still sitting at $0,08 and no buy out ?????

[subaru1i]

That is a good point that I have thought about as well and the only answer I can come up with is the regulatory/legal and even political environment.   I've been told twice now by those that know, Schedule 3 will happen and so that might put things in motion for us.   

[Solid1]

manipulation... and those who manipulate want to earn money and not in the cent range... the entire North American market lies at Labs' feet it is only a question of time here 

[Solid1]

And a manager like Pidduck doesn't show up at Labs and get paid with shares for which he then gets a few cents...? The man knows exactly how big the market for cannabinoids is. 

[subaru1i]

Over $25 Billion for cannabinoid pharmaceutical API's within the next 24 months.  Spectacular growth, explosive growth, disruptive technology growth.   Israel, Canada, Brazil, Germany Australia, and a few other smaller countries, those were the 'early adopters' and the next phase is the ramp up giving explosive growth....we've seen that already with the request into

[alleyesonme]

52 week high is .10c..considering multiple imminent events....10m Hexo settlement(1/3rd) of current market cap,  ...SEDDS capsule launch for clinical and adult use markets domestically and globally("second half 2023"),...ED mentioned ANVISA approval for NEW top 3, Brazilian generic pharma customer..Australian OTC approval..very long overdue..anyday IMO...cross integration of MPL and

[subaru1i]

You've summed it up very nicely and based on those FACTS and events now in motion, I personally think we will break out sometime this year.   The market is forward looking and institutional investors do not always wait for earnings to hit the bottom line when a company brings forth contracts that will be generating revenue to the bottom line like a goose that lays golden eggs. 

[checkup]

Canada's cannabis excise tax is draconian to say the least.  It is applied on the producer who has to pay before receiving payments for their products.  The government hasn't been able to recover 52 million in unpaid taxes.  There is no way that these companies can compete with the illiticit market. Not to mention the endless regulations on packaging etc. Canada has a really